- mAbxience will hold the marketing authorization for the biosimilar candidate in Croatia and Slovenia, while Corapharm will assume this role across Serbia, Bosnia and Herzegovina, North Macedonia, Montenegro, Kosovo, and Albania.
- This partnership combines mAbxience’s expertise in biosimilar development with Corapharm’s strong presence and commercial capabilities in these markets, aiming to improve patient access to advanced and affordable treatments.
Madrid, Spain, June 2nd, 2025 — mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Corapharm are pleased to announce a new strategic licensing agreement to develop and commercialize a biosimilar candidate in Southeast Europe.
Under the terms of the agreement, mAbxience will hold the marketing authorization for the biosimilar candidate in Croatia and Slovenia, while Corapharm will assume this role across Serbia, Bosnia and Herzegovina, North Macedonia, Montenegro, Kosovo, and Albania. Corapharm will lead commercialization efforts throughout these territories, with mAbxience overseeing the product’s development and manufacturing at its state-of-the-art facilities.
“We are excited to partner with Corapharm to bring this biosimilar candidate to patients across Southeast Europe. Our collaboration reflects mAbxience’s commitment to delivering high-quality, accessible therapies across various geographies,” said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.
“Building on our successful track record in the pharmaceutical industry, we look forward to working with mAbxience to improve patient outcomes and expand access to critical treatments in these countries,” noted Mr. Miroslav Roca, CEO of Corapharm d.o.o.. “Together, we remain dedicated to enhancing patient care and addressing the rising costs of biologic therapies.”
This agreement marks another milestone in mAbxience’s strategy to provide affordable, life-saving therapies worldwide. Both mAbxience and Corapharm expect that this partnership will enhance patient access to advanced treatments, while also helping healthcare systems manage the rising costs of biologic therapies.
About Corapharm
Corapharm is a leading pharmaceutical company with a strong presence in Southeast Europe specially knowledgeable on West Balkans territories plus Slovenia and Croatia. The company specializes in the commercialization and marketing of innovative therapies, aiming to improve patient outcomes and access to essential medicines. Corapharm’s extensive network and expertise in the region make it an ideal partner for bringing new treatments to market. For more details about Corapharm and its business capabilities, please visit www.corapharm.com or connect with them/us on LinkedIn.
About mAbxience
mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.
